Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. develops precision oncology medicines using its proprietary Generative Phosphoproteomics AP3 platform for drug design and predictive clinical development. The company’s recurring news centers on ACR-368, also known as prexasertib, a CHK1/2 inhibitor being developed with the ACR-368 OncoSignature assay for endometrial cancer, as well as ACR-2316, a WEE1/PKMYT1 inhibitor, and ACR-6840, a CDK11 development candidate.
Company updates commonly cover clinical and preclinical oncology data, scientific meeting presentations, FDA Fast Track and Breakthrough Device designations tied to ACR-368 and its assay, financial results, equity award disclosures, and the company’s internal CLIA-certified laboratory for patient testing and companion diagnostic development.
Acrivon Therapeutics (Nasdaq: ACRV) approved an inducement equity award under its 2023 Inducement Plan, consistent with Nasdaq Rule 5635(c)(4). One employee received stock options to purchase 111,150 shares at the May 15, 2026 Nasdaq closing price, with time-based vesting tied to continued employment.
Acrivon Therapeutics (Nasdaq: ACRV) reported first quarter 2026 results and pipeline progress. Net loss was $19.0 million, with R&D of $15.2 million and G&A of $4.7 million. Cash, equivalents and securities totaled $97.7 million plus $7.3 million from later equity financing, expected to fund operations into Q3 2027.
ACR-368 Phase 2b showed a 52% confirmed ORR in serous endometrial cancer vs 22% in non-serous. ACR-2316 Phase 1 reported favorable safety with transient neutropenia and durable activity in AP3-prioritized tumors, including small cell and squamous non-small cell lung cancers.
Acrivon (Nasdaq: ACRV) will present three preclinical posters at AACR 2026 (April 19–20) showing strong synergies of ACR-368 and ACR-2316 with anti-PD-L1 checkpoint inhibitors and synergy of ACR-368 with Topo 1 ADC payloads. Posters detail durable immune memory and rationale for frontline combination development.
Poster numbers: 239 (Apr 19), LB152 (Apr 20 AM), 3789 (Apr 20 PM).
Acrivon Therapeutics (Nasdaq: ACRV) approved an inducement equity award under its 2023 Inducement Plan on April 15, 2026. The company granted stock options to one employee to purchase 111,150 shares, with exercise price set at the Nasdaq closing price on the grant date and standard time-based vesting.
Acrivon Therapeutics (Nasdaq: ACRV) reported clinical and financial results on March 19, 2026. Key clinical data show a confirmed overall response rate (cORR) of 52% in serous endometrial cancer versus 22% in non-serous subjects. The company initiated Arm 3 in late 2025 and plans Arm 4 in H1 2026. Cash, cash equivalents and marketable securities totaled $118.6 million as of December 31, 2025, expected to fund operations into Q2 2027. Net loss was $19.0M for Q4 2025 and $77.9M for full-year 2025.
Acrivon Therapeutics (Nasdaq: ACRV) will present preclinical and late-breaking AACR 2026 data showing ACR-368 synergizes with Topo 1 ADC payloads and with PD-L1 blockade, and ACR-2316 plus anti-PD-L1 produced complete, durable tumor regressions in mouse models.
The company noted its AP3 platform guided these combination discoveries; ACR-368 is in a registrational-intent Phase 2b and ACR-2316 is in Phase 1.
Acrivon Therapeutics (Nasdaq: ACRV) will present at the TD Cowen 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 at 1:50 p.m. ET.
Peter Blume-Jensen, M.D., Ph.D., president and CEO, will appear in a fireside chat. A live and archived webcast will be available via the company's Events & Presentations investor webpage.
Acrivon (Nasdaq: ACRV) will host a live webcast KOL panel on February 27, 2026 at 8:00 a.m. ET to discuss maturing data from the registrational-intent Phase 2b ACR-368 endometrial cancer study and a late-breaking oral presentation at ESGO.
The event features international gynecologic oncology experts and an oral presentation of interim ACR-368 clinical data by Panos Konstantinopoulos, M.D., Ph.D. Webcast and archived video will be available via the company’s Events & Presentations investor page.
Acrivon Therapeutics (Nasdaq: ACRV) has completed and received CLIA certification for a wholly-owned clinical laboratory in Watertown, Massachusetts, expected to be fully operational in H1 2026. The facility will support patient testing and internal development of companion diagnostics.
The in-house CLIA lab aims to accelerate AP3-driven biomarker discovery, streamline co-regulatory workflows, and improve speed and cost-efficiency for precision medicine programs and potential partner collaborations.
Acrivon Therapeutics (Nasdaq: ACRV) announced a late-breaking oral presentation of interim clinical data for ACR-368 in endometrial cancer from its registrational-intent Phase 2b study (ACR-368-201/GOG3082, NCT05548296) at the ESGO 27th Annual Congress in Copenhagen, Feb 26-28, 2026.
Presenter Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., will present on Feb 27, 2026 at 12:05 p.m. CET (Presentation No. ESGO-2026-1321). The company described the interim data as a compelling clinical profile in a high unmet-need population.